Data on HSP70 involvement in Parkinson's disease (PD) pathogenesis, received in last 10 years, cannot answer the question whether the decrease in stress-inducible Hsp70 brain expression is one of the reasons for progressive neurodegeneration in PD. In the present study, the inhibitor of HSPs expression quercetin was used in a rat model of nigrostriatal system proteasome dysfunction. This model was created by the microinjections of the specific proteasome activity inhibitor lactacystin, that was injected locally to the substantia nigra pars compacta (SNpc). The model reproduces the under-threshold level of nigrostriatal degeneration and neurochemical features characteristic of the preclinical PD stage. It was shown for the first time that quercetin pretreatment inhibited the LC-induced expression of Hsp70 in the SNpc neurons and increased in 1.5 times the dopamine (DA)-ergic neurons death and in 2.7 times the striatal DA-ergic axons degeneration. These changes were accompanied by the depletion of compensatory mechanisms and HSP70 content in the SNpc neurons and the appearance of the motor dysfunctions, typical for the clinical PD stage. The results of this investigation indicate the important role of Hsp70 in mechanisms of the nigrostriatal system protection in proteasome dysfunction, characteristic for the pre-clinical PD stage. The data obtained can be considered as the scientific basis for the development of new technologies for early PD therapy by exogenous Hsp70.

Download full-text PDF

Source

Publication Analysis

Top Keywords

nigrostriatal system
12
proteasome dysfunction
8
snpc neurons
8
hsp70
6
[effect quercetin
4
quercetin neurodegenerative
4
neurodegenerative compensatory
4
compensatory processes
4
nigrostriatal
4
processes nigrostriatal
4

Similar Publications

Purpose: This study aimed to assess the association between motor and non-motor symptoms of Parkinson's disease (PD) and iron accumulation within the deep gray matter of the brain by Quantitative Susceptibility Mapping (QSM).

Methods: Fifty-six PD patients and twenty-nine healthy controls were recruited in this study. According to the Hoehn and Yahr (H-Y) stage score, PD patients were divided into early stage (H-Y ≤ 2) and advanced stage (H-Y > 2) groups.

View Article and Find Full Text PDF

Neurotransmitter and metabolic effects of interferon-alpha in association with decreased striatal dopamine in a Non-Human primate model of Cytokine-Induced depression.

Brain Behav Immun

January 2025

Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA; Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA. Electronic address:

Inflammatory stimuli administered to humans and laboratory animals affect mesolimbic and nigrostriatal dopaminergic pathways in association with impaired motivation and motor activity. Alterations in dopaminergic corticostriatal reward and motor circuits have also been observed in depressed patients with increased peripheral inflammatory markers. The effects of peripheral inflammation on dopaminergic pathways and associated neurobiologic mechanisms and consequences have been difficult to measure in patients.

View Article and Find Full Text PDF

Autism spectrum disorder (ASD) is a complex developmental disorder characterized by several behavioral impairments, especially in socialization, communication, and the occurrence of stereotyped behaviors. In rats, prenatal exposure to valproic acid (VPA) induces autistic-like behaviors. Previous studies by our group have suggested that the autistic-like phenotype is possibly related to dopaminergic system modulation because tyrosine hydroxylase (TH) expression was affected.

View Article and Find Full Text PDF

Parkinson's disease (PD) is the most prominent and highly prevalent chronic neuro-degenerative disease generally recognized by classical motor symptoms which are linked with genetic mutation, Lewy bodies, and subsequently selective loss of nigrostriatal dopaminergic neurons. The blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier protect the central nervous system against toxins and are the most significant barriers to effective brain drug delivery in managing Parkinsonism. In recent years, intranasal delivery has attracted remarkable attention for brain targeting as the drug can be administered to the brain directly from the nose employing the trigeminal and olfactory pathways.

View Article and Find Full Text PDF

Parkinson's disease (PD) is a neurodegenerative condition characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta (SNc) of the brain, manifesting itself with both motor and non-motor symptoms. A critical element of this pathology is neuroinflammation, which triggers a harmful neurotoxic cycle, exacerbating cell death within the central nervous system. AD-16 (also known as GIBH-130) is a recently identified compound capable of reducing the expression of pro-inflammatory cytokines while increasing the expression of anti-inflammatory cytokines in Alzheimer's disease models.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!